FDA Generics Director’s Departure Shows Why Chemistry Matters

Related Content

FDA’s Generics Office Loses Another Director As Geba Makes Quick Exit

CDER Taps Genzyme Exec As Deputy Director For Science Operations

GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm

Boehringer Ingelheim’s Me-Too Petition Against Generic Spiriva

Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline

Clinical Trials Not Required For Lidoderm Generics, FDA Tells Endo

FDA Office Of Generic Drugs Director Has Brand Industry Background

FDA's Woodcock Expresses Concern Not All Generics Are Equivalent, But OGD May Have Solution

FDA's Buehler To Join Teva

FDA's Generic Drugs Office Faces Transition As Director Buehler Departs